14.52 USD
0 (0%)
At close: Feb 9, 2026
14.52 USD
0 (0%)
After Hours: 2/9/2026, 8:00:01 PM
We assign a fundamental rating of 5 out of 10 to AMRX. AMRX was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of AMRX get a neutral evaluation. Nothing too spectacular is happening here. AMRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
- AMRX had positive earnings in the past year.
- AMRX had a positive operating cash flow in the past year.
- In multiple years AMRX reported negative net income over the last 5 years.
- In the past 5 years AMRX always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of AMRX (0.16%) is better than 77.49% of its industry peers.
- The Return On Invested Capital of AMRX (10.43%) is better than 90.05% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for AMRX is below the industry average of 12.63%.
- The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
- Looking at the Profit Margin, with a value of 0.20%, AMRX is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 12.32%, AMRX belongs to the top of the industry, outperforming 85.34% of the companies in the same industry.
- In the last couple of years the Operating Margin of AMRX has grown nicely.
- AMRX has a Gross Margin of 36.76%. This is in the better half of the industry: AMRX outperforms 60.21% of its industry peers.
- In the last couple of years the Gross Margin of AMRX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
- Compared to 1 year ago, AMRX has less shares outstanding
- AMRX has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, AMRX has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 1.99 indicates that AMRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 1.99, AMRX perfoms like the industry average, outperforming 59.69% of the companies in the same industry.
- AMRX has a debt to FCF ratio of 11.13. This is a negative value and a sign of low solvency as AMRX would need 11.13 years to pay back of all of its debts.
- The Debt to FCF ratio of AMRX (11.13) is better than 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | 1.99 |
ROIC/WACC1
WACC10.41%
2.3 Liquidity
- A Current Ratio of 2.13 indicates that AMRX has no problem at all paying its short term obligations.
- AMRX has a Current ratio of 2.13. This is in the lower half of the industry: AMRX underperforms 60.21% of its industry peers.
- AMRX has a Quick Ratio of 1.42. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.42, AMRX is doing worse than 65.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
- AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
- AMRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.63% yearly.
- AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.73%.
- AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
- AMRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.95% yearly.
- AMRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.60% yearly.
EPS Next Y40.2%
EPS Next 2Y28.34%
EPS Next 3Y26.83%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.6%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 19.36, AMRX is valued on the expensive side.
- Based on the Price/Earnings ratio, AMRX is valued cheaply inside the industry as 82.20% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 28.06. AMRX is valued slightly cheaper when compared to this.
- With a Price/Forward Earnings ratio of 15.20, AMRX is valued correctly.
- 82.20% of the companies in the same industry are more expensive than AMRX, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.86, AMRX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.36 | ||
| Fwd PE | 15.2 |
4.2 Price Multiples
- 86.39% of the companies in the same industry are more expensive than AMRX, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 86.39% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.3 | ||
| EV/EBITDA | 11.62 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- AMRX has a very decent profitability rating, which may justify a higher PE ratio.
- AMRX's earnings are expected to grow with 26.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.48
PEG (5Y)1.82
EPS Next 2Y28.34%
EPS Next 3Y26.83%
5. Dividend
5.1 Amount
- No dividends for AMRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.52
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-27 2026-02-27/bmo
Inst Owners45.17%
Inst Owner Change-0.26%
Ins Owners46.29%
Ins Owner Change-4.23%
Market Cap4.56B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts81.82
Price Target14.79 (1.86%)
Short Float %4.34%
Short Ratio2.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)3.57%
PT rev (3m)20.83%
EPS NQ rev (1m)-1.1%
EPS NQ rev (3m)0.33%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.36 | ||
| Fwd PE | 15.2 | ||
| P/S | 1.56 | ||
| P/FCF | 19.3 | ||
| P/OCF | 13.93 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.62 |
EPS(TTM)0.75
EY5.17%
EPS(NY)0.96
Fwd EY6.58%
FCF(TTM)0.75
FCFY5.18%
OCF(TTM)1.04
OCFY7.18%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.48
PEG (5Y)1.82
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 1.67 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.99 |
F-Score7
WACC10.41%
ROIC/WACC1
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.2%
EPS Next 2Y28.34%
EPS Next 3Y26.83%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.6%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.18%
EBIT Next 3Y10.07%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status for AMRX stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
How financially healthy is AMNEAL PHARMACEUTICALS INC?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.
Can you provide the expected EPS growth for AMRX stock?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.2% in the next year.